Issues related to corporate taxation including corporate rate; deductibility of research and development expenses; and international taxation (Foreign Derived Intangible Income).
2025 · 2nd Quarter (Apr 1 - June 30)
GENENTECH, INC.
Filed by HARBINGER STRATEGIES, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 22, 2025
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- HARBINGER STRATEGIES, LLC
- Client
- GENENTECH, INC.
- Filing UUID
- 0752a477-6829-4a30-bb14-29aa83fb795c
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to drug pricing. Issues related to the 340B Drug Discount Program.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.